Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)

Lawitz Eric; Yoshida Eric M.; Buti Maria; Vierling John M.; Almasio Piero L.; Bruno Savino; Ruane Peter J.; Hassanein Tarek I.; Lalezari Jacob P.; Mullhaupt Beat; Pearlman Brian; Gao Wei; Huang Hsueh-cheng; Shepherd Aimee; Tannenbaum Brynne; Fernsler Doreen; Li Jerry J.; Grandhi Anjana; Wan Shuyan; Dutko Frank; Yeh Wendy W.; Plank Rebeca; Nguyen Bach-Yen T.; Wahl Janice; Barr Eliav; Butterton Joan R.

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)

【24h】

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)

机译：MK-3682 / GrazoPrevir / MK-8408的固定剂量组合方案的安全性和有效性，在非肝硬化或肝硬化患者中有或没有利韦林患者慢性HCV GT1,2或3感染（C-Clest-1的第B部分） 2）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第s1期|共1页
作者
Lawitz Eric; Yoshida Eric M.; Buti Maria; Vierling John M.; Almasio Piero L.; Bruno Savino; Ruane Peter J.; Hassanein Tarek I.; Lalezari Jacob P.; Mullhaupt Beat; Pearlman Brian; Gao Wei; Huang Hsueh-cheng; Shepherd Aimee; Tannenbaum Brynne; Fernsler Doreen; Li Jerry J.; Grandhi Anjana; Wan Shuyan; Dutko Frank; Yeh Wendy W.; Plank Rebeca; Nguyen Bach-Yen T.; Wahl Janice; Barr Eliav; Butterton Joan R.;
展开▼
作者单位

Univ Texas Hlth Sci Ctr San Antonio Texas Liver Inst San Antonio TX 78229 USA;

Univ British Columbia Vancouver BC Canada;

Hosp Vall D Hebron Barcelona Spain;

Baylor Coll Med Adv Liver Therapies Houston TX 77030 USA;

UO Gastroenterol Palermo Italy;

IRCCS Ist Clin Humanitas &

Humanitas Univ Rozzano Italy;

Ruane Med &

Liver Hlth Inst Los Angeles CA USA;

Southern Calif GI Ctr Coronado CA USA;

Quest Clin Res San Francisco CA USA;

Univ Zurich Hosp Zurich Switzerland;

Atlanta Med Ctr Atlanta GA USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2) [J] . Lawitz Eric, Yoshida Eric M., Buti Maria, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：MK-3682 / GrazoPrevir / MK-8408的固定剂量组合方案的安全性和有效性，在非肝硬化或肝硬化患者中有或没有利韦林患者慢性HCV GT1,2或3感染（C-Clest-1的第B部分） 2）
2. Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2) [J] . Gane Edward J., Pianko Stephen, Roberts Stuart K., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2015,第6期

机译：Grazoprevir和MK-3682（NS5B聚合酶抑制剂）与Elbasvir或MK-8408（NS5A抑制剂）在慢性HCV GT1、2或3感染患者中的有效性和安全性的第2期随机对照临床试验C-CREST-1和2的A）
3. High Sustained Virologic Response (SVR) Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2) [J] . Serfaty Lawrence, Pianko Stephen, Ben Ari Ziv, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：在治疗失败后，在MK-3682 / GrazoPrevir / MK-8408加上利巴韦林患者慢性HCV GT1,2或3感染患者中的高持续的病毒学反应（SVR）率（C-C-C-C-C-C-1的第C部分）＆2）
4. Efficacy of combination therapy of interferon-α and ribavirin for HIV/HCV co-infected patients in a six-year follow-up [C] . AiPing Wang, ChunYang Wen, Fang Gao 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：六年随访中干扰素-α和利巴韦林联合治疗对HIV / HCV合并感染患者的疗效
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic chronic HCV infection without HBV co-infection [O] . Muhammad Baraa Hammami, Reem Aboushaar, Eyad Alsabbagh 2019

机译：Glecaprevir / pibrentasvir相关的急性肝损伤在非肝硬化慢性HCV感染没有HBV共感染
7. High Sustained Virologic Response (SVR) Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2) [O] . Serfaty, L., Pianko, S., Ben Ari, Z., 2016

机译：慢性HCV GT1,2或3感染患者的高持续病毒学应答（sVR）率16周后mK-3682 / Grazoprevir / mK-8408加利巴韦林治疗失败8周后（C-CREsT-1的C部分）＆amp; 2）

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)

著录项

引文网络

相似文献

相关主题

期刊订阅